Related Experiment Video
Updated: Jun 12, 2026
07:43
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.7K
Upadacitinib in refractory cutaneous pseudolymphoma: A case report
Elisabetta Danese1, Tea Curic1, Francesco Bellinato1
1Section of Dermatology and Venereology, Department of Medicine, University of Verona, Italy.
SAGE Open Medical Case Reports
|June 23, 2025
Summary
Cutaneous pseudolymphoma, a benign lymphoproliferative disorder, can be challenging to treat. This case highlights successful upadacitinib therapy for refractory facial IgG4-related pseudolymphoma.
Area of Science:
- Dermatology
- Immunology
- Pathology
Background:
- Cutaneous pseudolymphoma is a benign lymphoproliferative condition involving B-cells, T-cells, or both.
- Causes include injected substances, tattoos, drugs, or insect bites, but it's often idiopathic.
- Treatment guidelines are lacking, and some cases resist conventional therapies.
Observation:
- A 41-year-old African woman presented with refractory facial IgG4-related pseudolymphoma.
- The condition did not respond to standard treatment modalities.
Findings:
- Upadacitinib, a Janus kinase (JAK) inhibitor, demonstrated successful treatment in this refractory case.
- This indicates a potential new therapeutic avenue for similar presentations.
Implications:
- This case suggests upadacitinib may be an effective option for refractory cutaneous pseudolymphoma, particularly IgG4-related subtypes.
- Further research is warranted to explore JAK inhibitors in managing this rare condition.
- This finding could lead to improved treatment strategies and patient outcomes.
Related Concept Videos
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...